{
    "Trade/Device Name(s)": [
        "Access Free T4"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K240273",
    "Predicate Device Reference 510(k) Number(s)": [
        "K982250"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEC"
    ],
    "Summary Letter Date": "March 6, 2024",
    "Summary Letter Received Date": "January 31, 2024",
    "Submission Date": "January 31, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1695"
    ],
    "Regulation Name(s)": [
        "Free thyroxine test system"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Free thyroxine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (heparin)",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Access Immunoassay Systems",
        "Access 2 Immunoassay Analyzer",
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay",
        "Chemiluminescent immunoassay",
        "Automated"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Buffer",
        "Substrate"
    ],
    "Document Summary": "FDA 510(k) summary for Access Free T4 chemiluminescent immunoassay for quantitative determination of free thyroxine in serum and plasma on Access Immunoassay Systems",
    "Indications for Use Summary": "Quantitative determination of free thyroxine levels in human serum and plasma (heparin) for diagnosis and treatment of thyroid diseases using Access Immunoassay Systems",
    "fda_folder": "Clinical Chemistry"
}